Acuitas Therapeutics, the Vancouver, BC-based biotech company co-founded by NMIN research …
Previous
Next
Latest news...
“There is no time like the present to try to achieve …
NMIN’s Scientific Director Dr. Christine Allen has named Dr. Warren Chan …
The NanoMedicines Innovation Network (NMIN) is pleased to announce the inaugural …
NMIN is collaborating with its partner organization NanoCanada to build a …
The research in Small featured below is from the laboratories of …
NMIN submitted its second Annual Progress Report to the NCE on …
The NanoMedicines Innovation Network (NMIN) is pleased to announce the recipient …
The NanoMedicines Innovation Network (NMIN) is pleased to announce the inaugural …
The NanoMedicines Innovation Network (NMIN) is pleased to introduce the 2021-22 …
Top L to R: Brenna Rauw, Stephen Dibert, Inès Holzbaur, Wendy …
The NanoMedicines Innovation Network (NMIN), a national research network funded by …
Since news of the Pfizer-BioNTech COVID-19 vaccine first broke in November …
Three-minute knowledge translation videos created by NMIN HQP Dr. Shahla Shojaei …
L to R: Drs. Robert Hancock, Edward Sargent, Pieter Cullis, John …
Two new publications highlight recent research from the UBC-based lab of …
NMIN
about us
Advancing research, innovation and training in nanomedicines to maintain Canada as the world leader in the field.
The NanoMedicines Innovation Network (NMIN) is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.
NMIN brings Principal Investigators from institutions across Canada together with companies and not-for-profit research and granting institutions in a network committed to expanding and improving Canada’s position as a global leader in nanomedicines R&D.
NMIN is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
NMIN
Our focus
Develop nanomedicines
that enhance the therapeutic properties of small molecule drugs, and enable gene therapies.
Develop new diagnostics
that enable more precise disease detection and treatment, based on nanotechnology.
Train scientists
in the technology and business of nanomedicines, guided by market needs for HQP with skills required by the R&D community.
Translate nanomedicine
products and technologies, by implementing a cohesive IP and commercialization strategy.
NMIN
Management Team
Christine Allen
Scientific Director & CEO
Gilbert Walker
Associate Scientific Director
Diana Royce
Executive Director
NMIN
Contact
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
info@nanomedicines.ca